Senisca Ltd raises £3.7m seed money
Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2177 entries already.
Entries by Thomas Gabrielczyk
A novel BPM system
The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
Relation Therapeutics Ltd bags US$35m in seed financing.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
The EU Commission strikes again – New patent ban?
In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?
Scientists create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Swiss vaccine developer Limma Tech get CARB-X grant
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).